Adamis Pharmaceuticals Corporation
ADMP
$0.2113
-$0.0087-3.96%
| Weiss Ratings | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | D | |||
| Rating Factors | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | -- | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.46 | |||
| Price History | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 7.86% | |||
| 30-Day Total Return | 32.15% | |||
| 60-Day Total Return | 48.59% | |||
| 90-Day Total Return | -6.59% | |||
| Year to Date Total Return | 27.98% | |||
| 1-Year Total Return | -67.24% | |||
| 2-Year Total Return | -85.43% | |||
| 3-Year Total Return | -69.51% | |||
| 5-Year Total Return | -93.96% | |||
| 52-Week High % Change | -70.05% | |||
| 52-Week Low % Change | 83.33% | |||
| Price | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.73 | |||
| 52-Week Low Price | $0.12 | |||
| 52-Week Low Price (Date) | Oct 11, 2022 | |||
| 52-Week High Price (Date) | Mar 01, 2022 | |||
| Valuation | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $33.00M | |||
| Enterprise Value | 31.57M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.22 | |||
| Earnings Per Share Growth | -52.12% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 21.57 | |||
| Price/Book (Q) | 11.58 | |||
| Enterprise Value/Revenue (TTM) | 20.49 | |||
| Price | $0.21 | |||
| Enterprise Value/EBITDA (TTM) | -1.10 | |||
| Enterprise Value/EBIT | -1.05 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 149.983M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 997 2400 | |||
| Address | 11682 El Camino Real San Diego, CA 92130 | |||
| Website | www.adamispharmaceuticals.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,957.92% | |||
| Profit Margin | -2,072.23% | |||
| Management Effectiveness | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -65.90% | |||
| Return on Equity | -- | |||
| Income Statement | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $1.54M | |||
| Total Revenue (TTM) | $1.54M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | -$3.92M | |||
| EBITDA (TTM) | -$28.69M | |||
| EBIT (TTM) | -$30.16M | |||
| Net Income (TTM) | -$31.92M | |||
| Net Income Avl. to Common (TTM) | -$31.92M | |||
| Total Revenue Growth (Q YOY) | 98.12% | |||
| Earnings Growth (Q YOY) | 17.36% | |||
| EPS Diluted (TTM) | -$0.22 | |||
| EPS Diluted Growth (Q YOY) | 64.70% | |||
| Balance Sheet | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $2.42M | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | $10.09M | |||
| Total Preferred Equity (Q) | $0.16 | |||
| Total Equity (Q) | $3.00M | |||
| Current Ratio (Q) | 1.137 | |||
| Book Value Per Share (Q) | $0.02 | |||
| Total Assets (Q) | $12.14M | |||
| Total Current Liabilities (Q) | $8.87M | |||
| Total Debt (Q) | $840.10K | |||
| Total Liabilities (Q) | $9.13M | |||
| Total Common Equity (Q) | $2.85M | |||
| Cash Flow | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | $4.49M | |||
| Cash from Financing (TTM) | $242.20K | |||
| Net Change in Cash (TTM) | -$26.31M | |||
| Levered Free Cash Flow (TTM) | -$13.28M | |||
| Cash from Operations (TTM) | -$31.05M | |||
